Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JY025 combined with gefitinib or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer
CTR20211128Phase 2Active
- Sponsor
- Beijing Eastern Biotech
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JY025 in non-small cell lung cancer (NSCLC), sponsored by Beijing Eastern Biotech. Started Jun 2021; status: active.
02
Drugs
JY025
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211128.